| Current Price | $127.50 | Mkt Cap | $4.8B |
|---|---|---|---|
| Open | $119.56 | P/E Ratio | 0.00 |
| Prev. Close | $127.50 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $113.70 - $128.22 | Volume | 3,627,371 |
| 52-Wk Range | $2.78 - $132.96 | Avg. Daily Vol. | 3,282,575 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
| Current Price | $127.50 | Mkt Cap | $4.8B |
|---|---|---|---|
| Open | $119.56 | P/E Ratio | 0.00 |
| Prev. Close | $127.50 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $113.70 - $128.22 | Volume | 3,627,371 |
| 52-Wk Range | $2.78 - $132.96 | Avg. Daily Vol. | 3,282,575 |
The best Bull and Bear pitches based on recency and number of recommendations.
Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. As of December 31, 2009, the Company had four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a radio-labeled monoclonal antibody to treat… More
My 5 year old son just asked “what if we put a slice of turkey in the DVD player and it played a movie about the turkey’s whole life” and none of the parenting books I’ve read have prepared me for this question.
Read the most recent pitches from players about SAVA.
Recs
wpshil78
(33.17)
Submitted: 7/22/2021 10:06:08 AM :
Start Price:
$119.37
NASDAQ:SAVA Score:
+5.74
It's one drug candidate, Simufilam, looks like it's effective in the treatment of Alzheimers'. Phase III endpoints to be presented during the Summer 2021. This drug has massive potential.
Recs
TMFjimhalley
(37.08)
Submitted: 7/12/2021 6:46:55 PM :
Start Price:
$100.15
NASDAQ:SAVA Score:
+26.68
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
Recs
naughtyguy
(32.58)
Submitted: 3/20/2021 3:39:38 PM :
Start Price:
$57.03
NASDAQ:SAVA Score:
-111.02
This is WAY overbought!
Find the members with the highest scoring picks in SAVA.
medeaschild (76.09) Score: +16,574.83
The Score Leader is the player with the highest score across all their picks in SAVA.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| medeaschild | 76.09 | 12/26/2018 |
|
NS | $0.76 | +16,660.88% | +86.04% | +16,574.83 | 0 Comment | |
| SmallCapSurfer2 | 94.06 | 10/13/2016 |
|
3M | $5.32 | +2,296.62% | +106.92% | +2,189.69 | 0 Comment | |
| capptten | < 20 | 12/1/2020 |
|
3M | $7.66 | +1,564.49% | +20.09% | +1,544.40 | 1 Comment | |
| jornoski | 64.00 | 9/21/2020 |
|
5Y | $9.45 | +1,249.21% | +34.79% | +1,214.42 | 0 Comment | |
| OklaBoston | 64.19 | 9/21/2020 |
|
3Y | $9.45 | +1,249.21% | +34.79% | +1,214.42 | 1 Comment | |
| clangmead | 55.70 | 1/19/2021 |
|
5Y | $10.38 | +1,128.32% | +16.04% | +1,112.29 | 0 Comment | |
| dflo | 59.54 | 11/13/2014 |
|
5Y | $12.18 | +946.80% | +115.05% | +831.74 | 0 Comment | |
| VetteNV | 54.23 | 1/25/2021 |
|
3Y | $13.62 | +836.12% | +14.42% | +821.70 | 0 Comment | |
| Usualsspct | 91.27 | 1/25/2021 |
|
5Y | $13.62 | +836.12% | +14.42% | +821.70 | 0 Comment | |
| andythepandy | < 20 | 12/29/2014 |
|
NS | $14.07 | +806.18% | +110.84% | +695.34 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
